openPR Logo
Press release

Orphan Drugs Market Projected to Show Strong Growth by 2025| Key Players Novartis AG, F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, GlaxoSmithKline plc.

10-04-2019 03:14 PM CET | Health & Medicine

Press release from: Transparency Market Research

/ PR Agency: Transparency Market Research
Orphan Drugs Market

Orphan Drugs Market

Global Orphan Drugs Market: Overview

Orphan drug products are medicines for the therapy of life-threating or extremely severe illnesses or disorders which are uncommon for diagnosis, prevention or therapy. The pharmaceutical industry is little interested in the development and marketing of products designed for a tiny amount of patients under ordinary market circumstances. These medicines are called orphans. In 1983, the Orphan Drug Act was enacted to encourage drug companies to create rare disease therapy. The FDA Office for the Development of Orphan Products determines whether a drug is an orphan.

View Report: https://www.transparencymarketresearch.com/orphan-drugs-market.html

The incredibly high costs of placing a medicinal product on the market in drug companies would not be recovered from anticipated product revenues. This also leads to a small market potential for fresh drug use and an economic loss for the drug companies sector.

The worldwide orphan medicinal products market is expected to swell during the forecast period to give increasing significance to research and development operations. Over the forecast period 2017 to 2025 the international market for orphan drugs is expected to improve by 12.10 percent at CAGR. By the end of 2025, the worldwide market for orphan drugs should reach a net estimate of 318,5 billion US dollars.

The global orphan drugs market is segmented by the disease type, by indicator, and by technology for study. Further, the market is considered in terms of different geographical regions in the report.

Rising Prevalence of Rare Diseases to Strengthen Orphan Drugs Market

Recurring, chronic and rare illnesses and the elevated demand for significant amounts of orphan drug production are currently forecast to affect around 300 million people worldwide. Rare disease medicines, such as Yellow Fever, von Willebrand Disease, Waardenburg Syndrome, Diabetes Macular Edema, Abetalypoproteinemia, ASD, Yellow Nail Syndrome or Von Hippel Lindau Syndrome and others, are increasing in demand for medicinal products that help increase the market. In addition, FDA free exemptions, public R&D grants, favourable reimbursement policies and premium pricing for business development.

In 2019, it is likely that the U.S. will see around 1,762,450 new cancer cases, according to the National Center for Health Statistics. The demand for orphan medicines is likely to rise in the coming years as these figures are motivated. As a result, there have been a total of 4,171 drugs in the US as orphan drugs. Such Government initiatives encourage drug manufacturers to invest more in the said industry.

Request a Brochure of Orphan Drugs Market Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1254

Although the market for orphan medicines is developing at a decent rate, certain variables can impede its development. The elevated price of orphan medicines, inadequate data on rare illnesses and the absence of competent health experts are factors that reduce development in the worldwide market for orphan medicines. Furthermore, increasing competition from generic sectors can seriously threaten market growth.

Global Orphan Drugs Market: Regional Outlook

The global orphan drugs market is segmented for study into North America, Europe, and Rest of the World. Among these, North America is expected to register for high growth in the global market.

There are several factors contributing to the development of the industry, including promoting laws that enable rapid approval of such drugs, drug status exclusivity for such drugs and a solid medical infrastructure.

Global Orphan Drugs Market: Companies Mentioned

Key vendors profiled in our report on the global orphan drugs market include Novartis AG, F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, GlaxoSmithKline plc., Daiichi Sankyo Company Limited, Novo Nordisk A/S, Bayer AG, AstraZeneca plc., and Amgen Inc., among several others.

Contact Us

Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Orphan Drugs Market Projected to Show Strong Growth by 2025| Key Players Novartis AG, F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, GlaxoSmithKline plc. here

News-ID: 1843421 • Views: 539

More Releases from Transparency Market Research

Chatbot Market: Key Players and Production Information analysis
A 27.8% CAGR (Compound Annual Growth Rate) is set to mark the forecast period between 2016 and 2024, as per a Transparency Market Research (TMR) report. And, as per the analysts at TMR , some of the factors that the growth shall be attributed to are increasing popularity and adoption of Artificial Intelligence (AI) across industry verticals, including end-users, and innovation marking the landscape in a big way. This will
Digital Voice Recorder Market: Rising Allocations OnanalysisAnd Innovation
With the presence of a copious number of companies, the global market for digital voice recorder is fragmented with intense competition. In this scenario, top companies are aggressively engaged in technological advancements to serve ever-changing consumer demand, for which they are investing heavily in this market. In the years ahead, these players are likely to concentrate on regional expansion, for which they might resort to business alliances with regional players. Key
Virtual Reality (VR) in Healthcare Market - Global Industry Analysis, Size, Shar …
Global Virtual Reality (VR) in Healthcare Market - Overview The integration of IT solutions and principles in the field of healthcare is bringing about a transformation in the way patients are treated and services are provided by healthcare practitioners. The vast benefits of digitally managed processes and operations are prompting an increasing number of companies in the healthcare sector to shift from conventional manually operated devices and processes to newer and
Inertial Measurement Unit Market: A Latest Research Report to Share Industry Ins …
Growing at a stellar pace, Global Connected Logistics Market is set to increase the worth of the market, bringing it up to USD 55.17 billion by the end of the year 2025. This is a steep rise from 2016, when the market worth was USD 10.21 billion. This translates to an impressive 17.8% CAGR (Compound Annual Growth Rate) from 2017 to 2025. connected logistics market Technological Advancement to Propel Global Connected Logistics

All 5 Releases


More Releases for Orphan

Global Orphan Drug Pipeline & Regulatory Insight 2025
” Global Orphan Drug Pipeline & Regulatory Insight 2025” Report Highlights: Global Orphan Drug Market Overview: US$ 260 Billion Opportunity Global Orphan Drug market by Segment Regulatory Landscape: USA, Europe & Asia Orphan Drug Designation & Reimbursement Policy: USA, Europe & Asia Global Orphan Drug Clinical Pipeline Insight: 973 Drugs Marketed Orphan Drug Clinical Insight: 366 Drugs Download Report: http://www.pnspharma.com/buy-report.php?reporttitle=Global-Orphan-Drug-Pipeline-%26-Regulatory-Insight-2025 Report TOC Orphan Drugs: Regimens For Rare Diseases Drivers of Orphan Drug Commercialization 2.1 Cost
Global Orphan Drug Pipeline & Regulatory Insight 2025
” Global Orphan Drug Pipeline & Regulatory Insight 2025″ Report Highlights: Global Orphan Drug Market Overview: US$ 260 Billion Opportunity Global Orphan Drug market by Segment Regulatory Landscape: USA, Europe & Asia Orphan Drug Designation & Reimbursement Policy: USA, Europe & Asia Global Orphan Drug Clinical Pipeline Insight: 973 Drugs Marketed Orphan Drug Clinical Insight: 366 Drugs Download Report: http://www.pnspharma.com/buy-report.php?reporttitle=Global-Orphan-Drug-Pipeline-%26-Regulatory-Insight-2025 Orphan Drugs: Regimens For Rare Diseases Drivers of Orphan Drug Commercialization 2.1 Cost
US Orphan Drug Pipeline Analysis
In recent years, the pharmaceutical industry has been experiencing a paradigm shift. While a large pool of patients was considered as a major source of revenue for pharma companies in the past, the focus is now gradually shifting to small sections of patients suffering from rare disease. In US, this pool of patients is gradually growing and orphan drugs are becoming an extremely attractive business proposition for the pharmaceuticals industry.
Europe Orphan Drugs Pipeline Analysis
“Europe Orphan Drugs Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drug profiles under Orphan Drugs status in Europe. Research report covers all the ongoing drug development in various phases. Each drug profiles include detailed information like: Originator, Owner, Collaborator, Technology Provider, Licensee, Development Phase, Development Indications, Mechanism of Action, Chemical Formula, Country of Development and detailed analysis on the development process. The information for particular drug
Global Orphan Drug Pipeline Analysis
In recent years, the pharmaceutical industry has been experiencing a paradigm shift. While a large pool of patients was considered as a major source of revenue for pharma companies in the past, the focus is now gradually shifting to small sections of patients suffering from rare disease. In US & Europe, this pool of patients is gradually growing and orphan drugs are becoming an extremely attractive business proposition for the
Global Orphan Drug Clinical Pipeline Insight 2022
“Global Orphan Drug Clinical Pipeline Insight 2022” report gives comprehensive insight on various clinical and non-clinical aspects associated with ongoing clinical trials of 808 orphan designated drugs across the globe. The in-depth clinical insight presented in the report helps the reader to analyze and identify the various stakeholders involved in the clinical development and commercialization of orphan designated drugs in the global market. Currently there are more than 300 orphan